Breaking News Instant updates and real-time market news.

BIVV

Bioverativ

$50.76

-5.35 (-9.53%)

, RHHBY

Roche

$30.82

1.72 (5.91%)

18:08
11/20/17
11/20
18:08
11/20/17
18:08

Deutsche cuts Bioverativ target to $53 after positive Roche data

Deutsche Bank analyst Andrew Peters lowered his price target for Bioverativ (BIVV) to $53 from $65 and remains cautious on the shares following today's positive data from Roche's (RHHBY) Phase 3 study evaluating Hemlibra in noninhibitor hemophilia A patients. While full data is needed to better understand the clinical and competitive profile, the data reported today suggest Hemlibra will likely pressure the longevity and sustainability of Bioverativ's Eloctate franchise, Peters told investors earlier in a research note. The analyst reiterated a Hold rating on Bioverativ shares. The stock closed the trading day down 9.5% to $50.76. Shire (SHPG), another company with a hemophilia franchise, closed today down 4% to $141.37 while Roche rallied 6% to $30.82.

BIVV

Bioverativ

$50.76

-5.35 (-9.53%)

RHHBY

Roche

$30.82

1.72 (5.91%)

SHPG

Shire

$141.37

-6 (-4.07%)

  • 30

    Nov

  • 09

    Dec

  • 23

    Dec

  • 23

    Feb

BIVV Bioverativ
$50.76

-5.35 (-9.53%)

11/20/17
PIPR
11/20/17
NO CHANGE
Target $71
PIPR
Overweight
Piper a buyer of Bioverativ on Roche study selloff
Piper Jaffray analyst Christopher Raymond says he remains a buyer of Bioverativ (BIVV) after Roche (RHHBY) announced that its Haven 3 Phase III study met its primary endpoint. The analyst is waiting for the full data, expected in May, regarding absolute annualized bleed rates and consistency of effect. He remains confident in his forward estimates for Bioverativ's Eloctate and keeps an Overweight rating on the shares with a $71 price target. Absent full data detailing absolute annualized bleed rates for Roche's Hemlibra, it's difficult to draw too many conclusions on the relative efficacy compared to Eloctate in the non-inhibitor population, Raymond tells investors in a research note.
11/16/17
RBCM
11/16/17
NO CHANGE
RBCM
Top Pick
Roche approval neutral to slightly negative for Shire, says RBC Capital
RBC Capital analyst Douglas Miehm views the FDA approval for Roche's (RHHBY) Hemlibra as neutral to slight negative for Shire (SHPG). The approval comes three months early while the labeling for the hemophilia A drug contains a black box warning that severe blood clots may occur when Hemlibra is used with Feiba, Miehm tells investors in a research note. He believes investors will be "somewhat surprised" by the early timing of the approval but not surprised by the black box warning. He notes his estimates for Shire already reflect a 73% decline in inhibitor revenue from 2017 through 2025. Miehm keeps an Outperform rating on Shire. The stock in afternoon trading is up 5% to $146.66. Bioverativ (BIVV), another company with a hemophilia A treatment, is up 2% to $56.45.
10/27/17
PIPR
10/27/17
NO CHANGE
Target $71
PIPR
Overweight
Bioverativ selloff a 'golden' buying opportunity, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond contends that "nothing" on Bioverativ's earnings call would warrant the 7% selloff in the stock today and he believes a "misinterpretation" of the company's guidance may be the culprit. The fact that management did not update guidance and consensus is above the company's stated growth projection has caused some to interpret this as an implicit warning with respect to Q4 revenue, but Raymond doesn't think "management could have made it any clearer that Q417 expectations are safe." He recommends taking advantage of today's weakness and maintains an Overweight rating on Bioverativ shares with a $71 price target.
10/23/17
PIPR
10/23/17
INITIATION
Target $71
PIPR
Overweight
Bioverativ assumed with an Overweight at Piper Jaffray
Piper Jaffray analyst Christopher Raymond assumed coverage of Bioverativ with an Overweight rating and increased price target of $71. The analyst views the valuation as compelling given the company's base business and "still-underappreciated upside" from recent acquisitions.
RHHBY Roche
$30.82

1.72 (5.91%)

11/20/17
BTIG
11/20/17
NO CHANGE
Target $242
BTIG
Buy
Shire selloff on Roche news seems overdone, says BTIG
BTIG analyst Timothy Chiang said today's weakness in Shire (SHPG) shares is overdone and creates a potential buying opportunity. While Roche's (RHBBY) emicizumab is likely to gain share at the expense of Shire's Advate, he does not expect a rapid conversion and thinks Shire's pipeline and platform seem overly discounted at current levels. Chiang has a Buy rating and $242 price target on Shire shares.
11/16/17
CANT
11/16/17
NO CHANGE
Target $222
CANT
Overweight
Roche's black box warning positive for Shire, says Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen says the black box warning put on Roche's (RHHBY) Hemlibra by the FDA is a positive for Shire (SHPGY). The analyst believes the news supports her belief that concerns about competition for Shire's hemophilia franchise are overdone. Chen keeps an Overweight rating on Shire with a $222 price target. The stock in afternoon trading is up 4% to $146.13.
SHPG Shire
$141.37

-6 (-4.07%)

11/15/17
SUSQ
11/15/17
NO CHANGE
Target $225
SUSQ
Positive
Shire outlook remains underappreciated, says Susquehanna
Susquehanna analyst Andrew Finkelstein believes the outlook for Shire remain underappreciated. The analyst said the shares are trading at a low valuation and the company is well positioned for growth despite headwinds that are common across the sector. He sees growth accelerating and multiple levers to extend that runway. Finkelstein reiterated his Positive rating and $225 price target on Shire shares.

TODAY'S FREE FLY STORIES

HX

Hexindai

$11.17

0.04 (0.36%)

13:54
12/14/17
12/14
13:54
12/14/17
13:54
Initiation
Hexindai initiated  »

Hexindai initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IRBT

iRobot

$74.03

3.63 (5.16%)

13:51
12/14/17
12/14
13:51
12/14/17
13:51
Periodicals
Spruce Point mentions iRobot cautiously again »

The short-seller, which…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORCL

Oracle

$50.11

0.06 (0.12%)

, AMZN

Amazon.com

$1,164.13

-0.95 (-0.08%)

13:50
12/14/17
12/14
13:50
12/14/17
13:50
Earnings
On The Fly: What to watch for in Oracle's earnings report »

Oracle (ORCL) is…

ORCL

Oracle

$50.11

0.06 (0.12%)

AMZN

Amazon.com

$1,164.13

-0.95 (-0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 18

    Mar

CMCSA

Comcast

$38.58

-0.93 (-2.35%)

, CMCSK

Comcast

13:49
12/14/17
12/14
13:49
12/14/17
13:49
Hot Stocks
New York AG to lead multistate lawsuit to stop rollback of net neutrality »

New York Attorney General…

CMCSA

Comcast

$38.58

-0.93 (-2.35%)

CMCSK

Comcast

VZ

Verizon

$52.47

-0.42 (-0.79%)

T

AT&T

$37.89

-0.155 (-0.41%)

CHTR

Charter

$329.00

-0.99 (-0.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

, SPY

SPDR S&P 500 ETF Trust

$266.43

-0.32 (-0.12%)

13:46
12/14/17
12/14
13:46
12/14/17
13:46
Periodicals
Sen. Rubio a 'no' vote on current GOP tax bill, Washington Post reports »

Senator Marco Rubio told…

SPX

S&P 500

SPY

SPDR S&P 500 ETF Trust

$266.43

-0.32 (-0.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDXG

MiMedx

$11.99

-0.26 (-2.12%)

13:46
12/14/17
12/14
13:46
12/14/17
13:46
Periodicals
Short-seller Viceroy issues another report on MiMedx 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WBS

Webster Financial

$56.01

-0.15 (-0.27%)

13:45
12/14/17
12/14
13:45
12/14/17
13:45
Syndicate
Breaking Syndicate news story on Webster Financial »

Webster Financial files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

CMCSA

Comcast

$38.58

-0.93 (-2.35%)

13:44
12/14/17
12/14
13:44
12/14/17
13:44
Technical Analysis
Technical View: Comcast spikes as FCC repeals net neutrality »

The shares have spiked…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,040.61

0.13 (0.01%)

, GOOGL

Alphabet Class A

$1,051.39

2.62 (0.25%)

13:40
12/14/17
12/14
13:40
12/14/17
13:40
Hot Stocks
Google 'remains committed' to net neutrality, will work with other supporters »

Google's statement…

GOOG

Alphabet

$1,040.61

0.13 (0.01%)

GOOGL

Alphabet Class A

$1,051.39

2.62 (0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

  • 18

    Mar

SN

Sanchez Energy

$4.65

0.0246 (0.53%)

13:40
12/14/17
12/14
13:40
12/14/17
13:40
Options
Sanchez Energy sees repeat spread trading »

Sanchez Energy sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

NFLX

Netflix

$187.86

2.13 (1.15%)

13:38
12/14/17
12/14
13:38
12/14/17
13:38
Hot Stocks
Netflix says FCC decision on net neutrality 'beginning of longer legal battle' »

Netflix tweeted from its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMB

Kimberly-Clark

$117.84

0.4475 (0.38%)

13:34
12/14/17
12/14
13:34
12/14/17
13:34
Hot Stocks
EDF Renewable, Kimberly-Clark announce commercial operation at Rock Falls »

EDF Renewable Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MKGAY

Merck KGaA

13:28
12/14/17
12/14
13:28
12/14/17
13:28
Periodicals
Merck KGaA revives efforts to enter U.S. MS pill market, Reuters reports »

Merck KGaA is reviving…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRGO

Perrigo

$84.14

-1.88 (-2.19%)

, MKGAY

Merck KGaA

13:27
12/14/17
12/14
13:27
12/14/17
13:27
Periodicals
Perrigo prepping bid for Merck KGaA's consumer health division, Reuters reports »

Perrigo (PRGO) is…

PRGO

Perrigo

$84.14

-1.88 (-2.19%)

MKGAY

Merck KGaA

NSRGY

Nestle

$86.67

0.61 (0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CDE

Coeur Mining

$7.37

-0.01 (-0.14%)

13:25
12/14/17
12/14
13:25
12/14/17
13:25
Conference/Events
Coeur Mining to host business news update conference call »

Management provides an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

13:20
12/14/17
12/14
13:20
12/14/17
13:20
General news
U.S. equities sank back into the red »

U.S. equities sank back…

EE

El Paso Electric

$58.63

0.21 (0.36%)

13:17
12/14/17
12/14
13:17
12/14/17
13:17
Hot Stocks
El Paso Electric says Texas commission approves rate increase »

El Paso Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

13:17
12/14/17
12/14
13:17
12/14/17
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

13:16
12/14/17
12/14
13:16
12/14/17
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:15
12/14/17
12/14
13:15
12/14/17
13:15
General news
Treasury Action: yields have drifted lower from early highs »

Treasury Action: yields…

EPE

EP Energy

$1.66

-0.115 (-6.50%)

, CRZO

Carrizo Oil & Gas

$19.55

-1.03 (-5.00%)

13:13
12/14/17
12/14
13:13
12/14/17
13:13
Hot Stocks
EP Energy reports deal with Carrizo Oil to buy certain properties in Eagle Ford »

EP Energy Corporation…

EPE

EP Energy

$1.66

-0.115 (-6.50%)

CRZO

Carrizo Oil & Gas

$19.55

-1.03 (-5.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

BGCP

BGC Partners

$15.79

-0.61 (-3.72%)

13:13
12/14/17
12/14
13:13
12/14/17
13:13
Hot Stocks
BGC Partners sees Newmark IPO price at $14-$15 per share »

BGC Partners announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    May

T

AT&T

$37.97

-0.07 (-0.18%)

, CHTR

Charter

$329.00

-0.99 (-0.30%)

13:12
12/14/17
12/14
13:12
12/14/17
13:12
Hot Stocks
FCC repeals net neutrality in 3-2 vote along party lines »

This afternoon, after…

T

AT&T

$37.97

-0.07 (-0.18%)

CHTR

Charter

$329.00

-0.99 (-0.30%)

CMCSA

Comcast

$38.58

-0.93 (-2.35%)

CMCSK

Comcast

VZ

Verizon

$52.53

-0.365 (-0.69%)

NFLX

Netflix

$187.86

2.13 (1.15%)

GOOG

Alphabet

$1,040.61

0.13 (0.01%)

GOOGL

Alphabet Class A

$1,051.39

2.62 (0.25%)

AMZN

Amazon.com

$1,164.13

-0.95 (-0.08%)

FB

Facebook

$178.30

1.34 (0.76%)

TWTR

Twitter

$22.54

0.875 (4.04%)

DISH

Dish

$48.99

-0.64 (-1.29%)

SNE

Sony

$44.60

-0.055 (-0.12%)

ETSY

Etsy

$20.16

-0.05 (-0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jan

  • 07

    Feb

  • 18

    Mar

MAC

Macerich

$66.99

0.22 (0.33%)

13:10
12/14/17
12/14
13:10
12/14/17
13:10
Options
Notable call spreads in Macerich March options »

Notable call spreads in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:10
12/14/17
12/14
13:10
12/14/17
13:10
General news
FX Action: USD-JPY »

FX Action: USD-JPY…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.